Shares of Seattle Genetics (NASDAQ: SGEN) gained over 25% last month, according to data provided by S&P Global Market Intelligence. The company reported positive results from the HER2CLIMB clinical trial evaluating a combination therapy involving tucatinib, its lead drug candidate, to treat advanced breast cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,